Delivering Value for Injectables: Unmet Needs, Device Solutions and Therapy Outcomes

Printer-friendly version

What constitutes value today for an injectable drug or vaccine? That’s a question increasingly being asked by patients, prescribers and payers when it comes to the selection and use of injectable therapies. While upfront price will always be important, there are multiple other factors now being used by healthcare stakeholders to determine how a particular brand of injectable therapy should be valued against its competition. This article, from Stephen Allan, Senior Vice-President, Strategic Planning, Unilife Corporation, examines why pharmaceutical companies are leveraging innovative delivery systems to enhance and differentiate their injectable products so that they can generate powerful value-based healthcare outcomes amongst payers, prescribers and patients.